Both USPSTF and ASCO have released guidance on the use of medications to reduce breast cancer risk in women who meet a certain risk threshold. The USPSTF guidance is in alignment with ASCO in the recommendation of aromatase inhibitors, along with tamoxifen and raloxifene, as drugs suitable for use as risk-reducing medications for women at increased risk for breast cancer and at low risk for adverse medication effect (USPSTF Grade B offer or provide this service). Based on data review, the USPSTF and ASCO determined that certain medications have the potential to reduce the risk of estrogen receptor positive breast cancer by almost 50% in women. An individualized approach which integrates personal and family medical history is used to determine the best risk reduction approach.
- Provider:Postgraduate Institute for Medicine
- Activity Link: https://www.obgproject.com/2022/12/13/breast-cancer-risk-assessment-gail-model/
- Start Date: 2024-05-28 05:00:00
- End Date: 2024-05-28 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.2 hours - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all